OccuLogix cuts back
This article was originally published in The Gray Sheet
Executive Summary
OccuLogix fires seven members of its executive team in January following the indefinite suspension of clinical development for the RHEO blood filtration system to treat "dry" age-related macular degeneration. Also, CEO Elias Vamvakas and Chief Operating Officer Tom Reeves have agreed to take a 50% pay cut. The Toronto company announced plans for a 300-patient, sham-controlled pivotal trial of RHEO last February, but recently decided the project is not financially feasible following a review of the projected costs and development timeline (1"The Gray Sheet" Feb. 5, 2007, In Brief). The company also is exploring strategic alliances or selling all or part of the company. The firm sold its SOLX glaucoma business in December for $5 million plus future royalties. OccuLogix retains its San Diego-based OcuSense division, which plans to launch the TearLab diagnostic system in 2008. TearLab measures tear film osmolarity, a quantitative biomarker for dry eye
You may also be interested in...
OccuLogix Rheo trial
FDA approves an investigational device exemption for a 300-patient pivotal study of the firm's Rheo blood filtration system to treat the "dry" form of age-related macular degeneration, OccuLogix announces Jan. 29. Slated to begin this quarter, the multi-site, sham-controlled trial will evaluate vision improvement according to an acuity scale at one-year follow-up. The firm's previous trial for the device failed to meet its primary endpoint. Currently there is no FDA-approved treatment for dry AMD, which accounts for up to 90% of AMD patients, OccuLogix says...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.